WCA
CORT icon

Westover Capital Advisors’s Corcept Therapeutics CORT Stock Holding History

Westover Capital Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,835
Closed -$655K – 240
2025
Q4 		$655K Sell
18,835
-1,617
-8% -$127K 0.12% 127
2025
Q3 		$1.7M Sell
20,452
-215
-1% -$15.6K 0.31% 64
2025
Q2 		$1.52M Sell
20,667
-351
-2% -$25.4K 0.3% 71
2025
Q1 		$2.4M Buy
21,018
+5,431
+35% +$331K 0.53% 49
2024
Q4 		$785K Buy
15,587
+456
+3% +$23.9K 0.17% 112
2024
Q3 		$700K Buy
+15,131
New +$538K 0.13% 116

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Westover Capital Advisors's CORT Position: Q1 2026 in Review

Westover Capital Advisors sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 18,835 shares — an estimated $655K sold.

Westover Capital Advisors first reported a position in CORT in Q3 2024 and held it in 6 quarters. The position peaked at $2.4M in Q1 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Westover Capital Advisors reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Westover Capital Advisors sold 18,835 Corcept Therapeutics shares in Q1 2026, an estimated $655K.
  • Westover Capital Advisors first reported a position in Corcept Therapeutics in Q3 2024 and held it in 6 quarters.
  • Westover Capital Advisors's Corcept Therapeutics position peaked at $2.4M in Q1 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Westover Capital Advisors's 13F filing for Q1 2026, filed 5 May 2026.